Article Text

other Versions

PDF
Original article
Sex differences in cardiovascular outcome during progression of aortic valve stenosis
  1. Dana Cramariuc1,
  2. Barbara Patricia Rogge1,2,
  3. Mai Tone Lønnebakken2,
  4. Kurt Boman3,
  5. Edda Bahlmann4,
  6. Christa Gohlke-Bärwolf5,
  7. John B Chambers6,
  8. Terje R Pedersen7,
  9. Eva Gerdts2
  1. 1Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
  2. 2Department of Clinical Science, University of Bergen, Bergen, Norway
  3. 3Research unit, Medicine, Umeaa University, Skellefteaa, Sweden
  4. 4Asklepios Clinic St. Georg, Hamburg, Germany
  5. 5Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
  6. 6Guy's and St Thomas Hospitals, London, UK
  7. 7Department of Preventive Cardiology, Ullevål University Hopital, Oslo, Norway
  1. Correspondence to Dr Dana Cramariuc, Department of Heart Disease, Haukeland University Hospital, Bergen NO-5021, Norway; dana.cramariuc{at}helse-bergen.no

Abstract

Objective Women with severe aortic valve stenosis (AS) have better LV systolic function and more concentric LV geometry than their male counterparts. However, sex differences in cardiovascular (CV) outcome during progression of AS have not been reported from a longitudinal prospective study.

Methods Doppler echocardiography and CV events were recorded during a median of 4.0 years in 979 men and 632 women aged 28–86 (mean 67±10) years in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study. LV systolic function was assessed by EF and midwall shortening (MWS). Study outcomes were AS-related events, ischaemic CV events and total mortality.

Results The annular cumulative incidence of AS events, ischaemic CV events and death was 8.1%, 3.4% and 2.8% in women, and 8.9%, 4.4% and 2.4% in men, respectively. Women and men had similar AS progression rate whether measured by peak jet velocity, mean gradient or valve area. In multivariate analyses, female sex independently predicted less reduction in LV MWS and EF during follow-up (both p<0.05). In time-varying Cox analyses, women had a 40% lower rate of ischaemic CV events (95% CI 21% to 54%), in particular, more than 50% lower rate of stroke and coronary artery bypass grafting, and a 31% lower all-cause mortality (95% CI 1% to 51%), independent of active study treatment, age and hypertension, as well as time-varying valve area, low systolic function and abnormal LV geometry. AS event rate did not differ by sex.

Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders.

Trial registration number ClinicalTrials.gov identifier: NCT00092677.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles